These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

62 related items for PubMed ID: 3566291

  • 1. [Experimental studies on the enhanced effects of chemoendocrine therapy in breast cancer].
    Abe R, Sawano A, Ueki H, Akimoto M, Kimura M.
    Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 2):785-92. PubMed ID: 3566291
    [Abstract] [Full Text] [Related]

  • 2. [Synergistic effect of cell kinetics-directed chemo-endocrine therapy on experimental mammary tumors].
    Ueki H.
    Nihon Geka Gakkai Zasshi; 1987 Nov; 88(11):1576-83. PubMed ID: 3431537
    [Abstract] [Full Text] [Related]

  • 3. [Synergistic action of lentinan (LNT) with endocrine therapy of breast cancer in rats and humans].
    Kosaka A, Kuzuoka M, Yamafuji K, Imaizumi A, Hattori Y, Yamashita A.
    Gan To Kagaku Ryoho; 1987 Feb; 14(2):516-22. PubMed ID: 3101609
    [Abstract] [Full Text] [Related]

  • 4. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
    Viale G, Regan MM, Maiorano E, Mastropasqua MG, Golouh R, Perin T, Brown RW, Kovács A, Pillay K, Ohlschlegel C, Braye S, Grigolato P, Rusca T, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson BA, Coates AS.
    J Clin Oncol; 2008 Mar 20; 26(9):1404-10. PubMed ID: 18349391
    [Abstract] [Full Text] [Related]

  • 5. Tamoxifen and 5-fluorouracil in breast cancer: cytotoxic synergism in vitro.
    Benz C, Cadman E, Gwin J, Wu T, Amara J, Eisenfeld A, Dannies P.
    Cancer Res; 1983 Nov 20; 43(11):5298-303. PubMed ID: 6616464
    [Abstract] [Full Text] [Related]

  • 6. Management of breast cancer.
    Cohen IA, Keller JH, Abate MA.
    Clin Pharm; 1982 Nov 20; 1(6):515-29. PubMed ID: 6192963
    [Abstract] [Full Text] [Related]

  • 7. Combination therapy of the H2712 murine mammary carcinoma with cytotoxic T lymphocytes and anti-estrogens.
    Baral E, Nagy E, Kangas L, Berczi I.
    Anticancer Res; 1997 Nov 20; 17(5A):3647-51. PubMed ID: 9413217
    [Abstract] [Full Text] [Related]

  • 8. Human breast cancer cell cycle synchronization by estrogens and antiestrogens in culture.
    Osborne CK, Boldt DH, Estrada P.
    Cancer Res; 1984 Apr 20; 44(4):1433-9. PubMed ID: 6704960
    [Abstract] [Full Text] [Related]

  • 9. [Breast cancer--topics from basic research].
    Matsumoto K, Kuroda H, Takeyama M.
    Gan To Kagaku Ryoho; 1984 May 20; 11(5):974-80. PubMed ID: 6721515
    [Abstract] [Full Text] [Related]

  • 10. Content of epidermal growth factor receptor in metastatic breast cancer: its role in endocrine sensitivity prediction.
    Nesković-Konstantinović ZB, Nikolić-Vukosavljević DB, Branković-Magić MV, Mitrovic LB, Spuzić I.
    Neoplasma; 2000 May 20; 47(2):107-13. PubMed ID: 10985476
    [Abstract] [Full Text] [Related]

  • 11. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice.
    Yao K, Lee ES, Bentrem DJ, England G, Schafer JI, O'Regan RM, Jordan VC.
    Clin Cancer Res; 2000 May 20; 6(5):2028-36. PubMed ID: 10815929
    [Abstract] [Full Text] [Related]

  • 12. Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.
    Hoffmann J, Sommer A.
    J Steroid Biochem Mol Biol; 2005 Feb 20; 93(2-5):191-200. PubMed ID: 15860262
    [Abstract] [Full Text] [Related]

  • 13. The efficacy of tamoxifen in estrogen receptor-positive breast cancer cells is enhanced by a medical nutriment.
    Marcsek Z, Kocsis Z, Jakab M, Szende B, Tompa A.
    Cancer Biother Radiopharm; 2004 Dec 20; 19(6):746-53. PubMed ID: 15665622
    [Abstract] [Full Text] [Related]

  • 14. [Modulation of the anti-tumor effect of BRM under various nutritional or endocrine conditions].
    Akimoto M, Nishihira T, Kasai M.
    Gan To Kagaku Ryoho; 1986 Apr 20; 13(4 Pt 2):1270-6. PubMed ID: 3729450
    [Abstract] [Full Text] [Related]

  • 15. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188).
    Davidson NE, O'Neill AM, Vukov AM, Osborne CK, Martino S, White DR, Abeloff MD.
    J Clin Oncol; 2005 Sep 01; 23(25):5973-82. PubMed ID: 16087950
    [Abstract] [Full Text] [Related]

  • 16. Differential sensitivity of human breast cancer cell lines to the growth-inhibitory effects of tamoxifen.
    Reddel RR, Murphy LC, Hall RE, Sutherland RL.
    Cancer Res; 1985 Apr 01; 45(4):1525-31. PubMed ID: 3978620
    [Abstract] [Full Text] [Related]

  • 17. Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo.
    Dardes RC, O'Regan RM, Gajdos C, Robinson SP, Bentrem D, De Los Reyes A, Jordan VC.
    Clin Cancer Res; 2002 Jun 01; 8(6):1995-2001. PubMed ID: 12060645
    [Abstract] [Full Text] [Related]

  • 18. [Present status of endocrine therapy of breast cancer: a surgeon's view].
    Nomura Y.
    Gan To Kagaku Ryoho; 1984 May 01; 11(5):981-8. PubMed ID: 6426405
    [Abstract] [Full Text] [Related]

  • 19. [Internal endocrine therapy of breast cancer].
    Yoshida M, Miura S.
    Gan To Kagaku Ryoho; 1984 May 01; 11(5):989-98. PubMed ID: 6372698
    [Abstract] [Full Text] [Related]

  • 20. Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas.
    Makris A, Powles TJ, Dowsett M, Osborne CK, Trott PA, Fernando IN, Ashley SE, Ormerod MG, Titley JC, Gregory RK, Allred DC.
    Clin Cancer Res; 1997 Apr 01; 3(4):593-600. PubMed ID: 9815725
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.